Company: KROS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001664710-25-000018
Chunk: 167

Company: Keros Therapeutics, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 15
Chunk 167
---
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a) The following documents are filed as part of this Annual Report on Form 10-K:

(1) The Consolidated Financial Statements required to be filed by Item 8 of this Annual Report on Form 10-K, and filed in this Item 15, are as follows:

PAGEReport of Independent Registered Public Accounting Firm (PCAOB ID 34)F-2Consolidated Balance SheetsF-4Consolidated Statements of OperationsF-5Consolidated Statements of Stockholders’ EquityF-6Consolidated Statements of Cash FlowsF-7Notes to Consolidated Financial StatementsF-8

(2) The Consolidated Financial Statement Schedule have been omitted because they are either not applicable or the required information is included in the Consolidated Financial Statements or notes thereto listed in (a)(1) above.

(3) Exhibits are incorporated herein by reference or are filed with this Annual Report on Form 10-K as indicated below

(b) Exhibits

EXHIBITNO.DESCRIPTIONFORMFILE NO.EXHIBITFILING DATE3.1Amended and Restated Certificate of Incorporation of the Registrant.8-K001-392643.1April 13, 20203.2Amended and Restated Bylaws of the Registrant.8-K001-392643.2April 13, 20204.1Amended and Restated Investors’ Rights Agreement by and among the registrant and certain of its stockholders, dated as of March 2, 2020.S-1333-2372124.1March 16, 20204.2Form of Common Stock Certificate.S-1/A333-2372124.2April 1, 20204.3*Description of the Registrant’s Securities.10.1Form of Indemnity Agreement between the registrant and its directors and officers.S-1/A333-23721210.1April 1, 202010.2+2017 Stock Incentive Plan, as amended.S-1333-23721210.2March 16, 202010.3+Form of Stock Option Grant Notice and Option Agreement for the 2017 Stock Incentive Plan, as amended.S-1333-23721210.3March 16, 202010.4+2020 Equity Incentive Plan.S-1/A333-237212